Organogenesis Holdings Inc. (ORGO)

Market Cap	574.65M
Revenue (ttm)	458.76M
Net Income (ttm)	-20.43M
Shares Out	126.85M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	50.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	462,405
Open	4.640
Previous Close	4.600
Day's Range	4.495 - 4.670
52-Week Range	2.280 - 6.710
Beta	1.77
Analysts	Buy
Price Target	6.50 (+43.49%)
Earnings Date	Aug 7, 2025

About ANSS

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic fo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 869
• Stock Exchange: NASDAQ
• Ticker Symbol: ORGO
• Website: https://organogenesis.com

Analyst Summary

According to 2 analysts, the average rating for ORGO stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 43.49% from the latest price.

Price Target

$6.5

(43.49% upside)

Analyst Consensus: Buy